Health Canada’s Summary Basis of Decision (SBD) documents outline the scientific and
regulatory considerations that factor into Health Canada regulatory decisions related to drugs and
medical devices. Mozobil is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to
mobilize haematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent
autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple
myeloma (MM). Read the full document
here.